Immunotherapy for myeloproliferative neoplasms (MPN)

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 72-84

  Hofmann, Susanne ^a   Babiak, Anna ^a   Greiner, Jochen ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

CML; Immunotherapy; Leukaemia associated antigen (LAA); Myeloproliferative neoplasms (MPN); Vaccine

Indexed keywords

AG 858; ALPHA INTERFERON; DASATINIB; DENDRITIC CELL VACCINE; IMATINIB; IMMUNOMODULATING AGENT; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LEUKEMIA ANTIGEN; NILOTINIB; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLITIS; DONOR LYMPHOCYTE INFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTOSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PLEURA EFFUSION; PLEURISY; POLYCYTHEMIA VERA; T LYMPHOCYTE; THROMBOCYTHEMIA; VACCINATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS;

EID: 78951485868     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743682     Document Type: Article

References (139)

1. Vardiman, J. W.; Thiele, J.; Arber, D. A.; Brunning, R. D.; Borowitz, M. J.; Porwit, A.; Harris, N. L.; Le Beau, M. M.; Hellstrom-Lindberg, E.; Tefferi, A.; Bloomfield, C. D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5), 937-951.
2. Gilliland, D. G.; Blanchard, K. L.; Levy, J.; Perrin, S.; Bunn, H. F. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc. Natl. Acad. Sci. U S A 1991, 88(15), 6848-6852.
3. Fialkow, P. J.; Jacobson, R. J.; Papayannopoulou, T. Chronic mye-locytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1977, 63(1), 125-130.
4. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluo-rescence and Giemsa staining. Nature 1973, 243(5405), 290-293.
5. Cools, J.; DeAngelo, D. J.; Gotlib, J.; Stover, E. H.; Legare, R. D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky, I.; Griffin, J. D.; Cross, N. C.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S. L.; Schmid, J.; Rose, M.; Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodar-ska, I.; Kantarjian, H.; Marynen, P.; Coutre, S. E.; Stone, R.; Gilliland, D. G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348(13), 1201-1214.
6. Nagata, H.; Worobec, A. S.; Oh, C. K.; Chowdhury, B. A.; Tannenbaum, S.; Suzuki, Y.; Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 1995, 92(23), 10560-10564.
7. Kralovics, R.; Passamonti, F.; Buser, A. S.; Teo, S. S.; Tiedt, R.; Passweg, J. R.; Tichelli, A.; Cazzola, M.; Skoda, R. C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352(17), 1779-1790.
8. Pardanani, A. D.; Levine, R. L.; Lasho, T.; Pikman, Y.; Mesa, R. A.; Wadleigh, M.; Steensma, D. P.; Elliott, M. A.; Wolanskyj, A. P.; Hogan, W. J.; McClure, R. F.; Litzow, M. R.; Gilliland, D. G.; Tefferi, A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108(10), 3472-3476.
9. Greiner, J.; Ringhoffer, M.; Taniguchi, M.; Li, L.; Schmitt, A.; Shiku, H.; Dohner, H.; Schmitt, M. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int. J. Cancer 2004, 108(5), 704-711.
10. Greiner, J.; Schmitt, M.; Li, L.; Giannopoulos, K.; Bosch, K.; Schmitt, A.; Dohner, K.; Schlenk, R. F.; Pollack, J. R.; Dohner, H.; Bullinger, L. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108(13), 4109-4117.
11. Greiner, J.; Schmitt, M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leuke-mia. Eur. J. Haematol. 2008, 80(6), 461-468.
12. Xiong, Z.; Yan, Y.; Liu, E.; Silver, R. T.; Verstovsek, S.; Yang, F.; Wang, H.; Prchal, J.; Yang, X. F. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with poly-cythemia vera. Clin. Immunol. 2007, 122(3), 279-287.
13. Greiner, J.; Dohner, H.; Schmitt, M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated an-tigens and current clinical protocols targeting these antigens. Hae-matologica 2006, 91(12), 1653-1661.
14. Guinn, B.; Greiner, J.; Schmitt, M.; Mills, K. I. Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 2009, 113(5), 1203-1204.
15. Steinbach, D.; Hermann, J.; Viehmann, S.; Zintl, F.; Gruhn, B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet. Cytogenet. 2002, 133(2), 118-123.
16. Radich, J. P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C. L.; Friend, S.; Linsley, P. S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2006, 103(8), 2794-2799.
17. Hernandez-Boluda, J. C.; Bellosillo, B.; Vela, M. C.; Colomer, D.; Alvarez-Larran, A.; Cervantes, F. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk. Lymphoma 2005, 46(5), 717-722.
18. Yong, A. S.; Rezvani, K.; Savani, B. N.; Eniafe, R.; Mielke, S.; Goldman, J. M.; Barrett, A. J. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 2007, 110(2), 770-775.
19. A prospective comparison of alpha-IFN and conventional chemo-therapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Haematologica 1992, 77(3), 204-214.
20. Hehlmann, R.; Berger, U.; Pfirrmann, M.; Heimpel, H.; Hochhaus, A.; Hasford, J.; Kolb, H. J.; Lahaye, T.; Maywald, O.; Reiter, A.; Hossfeld, D. K.; Huber, C.; Loffler, H.; Pralle, H.; Queisser, W.; Tobler, A.; Nerl, C.; Solenthaler, M.; Goebeler, M. E.; Griessham-mer, M.; Fischer, T.; Kremers, S.; Eimermacher, H.; Pfreundschuh, M.; Hirschmann, W. D.; Lechner, K.; Wassmann, B.; Falge, C.; Kirchner, H. H.; Gratwohl, A. Drug treatment is superior to al-lografting as first-line therapy in chronic myeloid leukemia. Blood 2007, 109(11), 4686-4692.
21. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107(11), 4532-4539.
22. Essers, M. A.; Offner, S.; Blanco-Bose, W. E.; Waibler, Z.; Kalinke, U.; Duchosal, M. A.; Trumpp, A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458(7240),904-908.
23. Graham, S. M.; Jorgensen, H. G.; Allan, E.; Pearson, C.; Alcorn, M. J.; Richmond, L.; Holyoake, T. L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leu-kemia are insensitive to STI571 in vitro. Blood 2002, 99(1), 319-325.
24. Rousselot, P.; Huguet, F.; Rea, D.; Legros, L.; Cayuela, J. M.; Maarek, O.; Blanchet, O.; Marit, G.; Gluckman, E.; Reiffers, J.; Gardembas, M.; Mahon, F. X. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecularremission for more than 2 years. Blood 2007, 109(1), 58-60.
25. Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J.Clin. Oncol. 2009, 27(35), 6041-6051.
26. Mahon, F. X.; Delbrel, X.; Cony-Makhoul, P.; Faberes, C.; Boiron, J. M.; Barthe, C.; Bilhou-Nabera, C.; Pigneux, A.; Marit, G.; Reiffers, J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J. Clin. Oncol. 2002, 20(1), 214-220.
27. Burchert, A.; Muller, M. C.; Kostrewa, P.; Erben, P.; Bostel, T.; Liebler, S.; Hehlmann, R.; Neubauer, A.; Hochhaus, A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 2010, 28(8), 1429-1435.
28. Molldrem, J.; Dermime, S.; Parker, K.; Jiang, Y. Z.; Mavroudis, D.; Hensel, N.; Fukushima, P.; Barrett, A. J. Targeted T-cell the-rapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88(7), 2450-2457.
29. Burchert, A.; Wolfl, S.; Schmidt, M.; Brendel, C.; Denecke, B.; Cai, D.; Odyvanova, L.; Lahaye, T.; Muller, M. C.; Berg, T.; Gschaidmeier, H.; Wittig, B.; Hehlmann, R.; Hochhaus, A.; Neubauer, A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T- cell response in chronic myeloid leukemia. Blood 2003, 101(1), 259-264.
30. Kanodia, S.; Wieder, E.; Lu, S.; Talpaz, M.; Alatrash, G.; Clise-Dwyer, K.; Molldrem, J. J. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leu-kemia after interferon withdrawal. PLoS One 2010, 5(7), e11770
31. Oka, T.; Sastry, K. J.; Nehete, P.; Schapiro, S. J.; Guo, J. Q.; Talpaz, M.; Arlinghaus, R. B. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 1998, 12(2), 155-163.
32. Molldrem, J. J.; Lee, P. P.; Wang, C.; Felio, K.; Kantarjian, H. M.; Champlin, R. E.; Davis, M. M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000, 6(9), 1018-1023.
33. Sacchi, S.; Kantarjian, H.; O'Brien, S.; Cohen, P. R.; Pierce, S.; Talpaz, M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol. 1995, 13(9), 2401-2407.
34. Boissel, N.; Rousselot, P.; Raffoux, E.; Cayuela, J. M.; Soulier, J.; Mooney, N.; Charron, D.; Dombret, H.; Toubert, A.; Rea, D. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukoc. Biol. 2006, 79(4), 747-756.
35. Seggewiss, R.; Lore, K.; Greiner, E.; Magnusson, M. K.; Price, D. A.; Douek, D. C.; Dunbar, C. E.; Wiestner, A., Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105(6), 2473-2479.
36. Dietz, A. B.; Souan, L.; Knutson, G. J.; Bulur, P. A.; Litzow, M. R.; Vuk-Pavlovic, S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004, 104(4), 1094-1099.
37. Chen, J.; Schmitt, A.; Chen, B.; Rojewski, M.; Ringhoffer, M.; von Harsdorf, S.; Greiner, J.; Guillaume, P.; Dohner, H.; Bunjes, D.; Schmitt, M. Imatinib impairs CD8 T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol. Immunother. 2007, 56(6), 849-861.
38. Appel, S.; Boehmler, A. M.; Grunebach, F.; Muller, M. R.; Rupf, A.; Weck, M. M.; Hartmann, U.; Reichardt, V. L.; Kanz, L.; Brummendorf, T. H.; Brossart, P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004, 103(2), 538-544.
39. Bocchia, M.; Abruzzese, E.; Forconi, F.; Ippoliti, M.; Trawinska, M. M.; Pirrotta, M. T.; Raspadori, D.; Tozzi, M.; Gozzetti, A.; Lauria, F. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 2006, 20(1), 142-143.
40. Brauer, K. M.; Werth, D.; von Schwarzenberg, K.; Bringmann, A.; Kanz, L.; Grunebach, F.; Brossart, P. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer. Res. 2007, 67(11), 5489-5497.
41. Larmonier, N.; Janikashvili, N.; LaCasse, C. J.; Larmonier, C. B.; Cantrell, J.; Situ, E.; Lundeen, T.; Bonnotte, B.; Katsanis, E. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J. Immunol. 2008, 181(10), 6955-6963.
42. Bocchia, M.; Gentili, S.; Abruzzese, E.; Fanelli, A.; Iuliano, F.; Tabilio, A.; Amabile, M.; Forconi, F.; Gozzetti, A.; Raspadori, D.; Amadori, S.; Lauria, F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365(9460), 657-662.
43. Li, Z.; Qiao, Y.; Liu, B.; Laska, E. J.; Chakravarthi, P.; Kulko, J. M.; Bona, R. D.; Fang, M.; Hegde, U.; Moyo, V.; Tannenbaum, S. H.; Menoret, A.; Gaffney, J.; Glynn, L.; Runowicz, C. D.; Srivastava, P. K. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 2005, 11(12), 4460-4468.
44. Hino, M.; Futami, E.; Okuno, S.; Miki, T.; Nishizawa, Y.; Morii, H., Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann. Hematol. 1993, 66(3), 161-162.
45. Massaro, P.; Foa, P.; Pomati, M.; LaTargia, M. L.; Iurlo, A.; Clerici, C.; Caldiera, S.; Fornier, M.; Maiolo, A. T. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am. J. Hematol. 1997, 56(2), 126-128.
46. Huang, J. W.; Xu, J. In vitro effect of interferon alpha on proliferation of human marrow fibroblast. Zhonghua. Xue. Ye. Xue. Za. Zhi. 2004, 25(8), 478-481.
47. Tefferi, A.; Elliot, M. A.; Yoon, S. Y.; Li, C. Y.; Mesa, R. A.; Call, T. G.; Dispenzieri, A. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001, 97(6), 1896.
48. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354(24), 2531-2541.
49. Apperley, J. F.; Cortes, J. E.; Kim, D. W.; Roy, L.; Roboz, G. J.; Rosti, G.; Bullorsky, E. O.; Abruzzese, E.; Hochhaus, A.; Heim, D.; de Souza, C. A.; Larson, R. A.; Lipton, J. H.; Khoury, H. J.; Kim, H. J.; Sillaber, C.; Hughes, T. P.; Erben, P.; Van Tornout, J.; Stone, R. M. Dasatinib in the treatment of chronic myeloid leuke-mia in accelerated phase after imatinib failure: the START a trial. J. Clin. Oncol. 2009, 27(21), 3472-3479.
50. Kantarjian, H. M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F. E.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110(10), 3540-3546.
51. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J. D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann, O. G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354(24), 2542-2551.
52. Blake, S. J.; Lyons, A. B.; Hughes, T. P. Nilotinib inhibits the Srcfamily kinase LCK and T-cell function in vitro. J. Cell. Mol. Med. 2009, 13(3), 599-601.
53. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-aminothiazole as a novel kinase inhibitor template. Structureactivity relationship studies toward the discovery of N-(2-chloro-6- methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl- 4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006, 49(23), 6819-6832.
54. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2), 129-141.
55. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Greiner, J.; Gotz, M.; Bunjes, D.; Schmitt, M. Effects of nilotinib on regulatory T cells: the dose matters. Mol. Cancer 2010, 9, 22-26.
56. Palacios, E. H.; Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23(48), 7990-8000.
57. Lee, K. C.; Ouwehand, I.; Giannini, A. L.; Thomas, N. S.; Dibb, N. J.; Bijlmakers, M. J. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010, 24(4), 896-900.
58. Schade, A. E.; Schieven, G. L.; Townsend, R.; Jankowska, A. M.; Susulic, V.; Zhang, R.; Szpurka, H.; Maciejewski, J. P. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008, 111(3), 1366-1377.
59. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Gotz, M.; Dohner, H.; Bunjes, D.; Schmitt, M. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br. J. Haematol. 2009, 144(2), 195-205.
60. Fei, F.; Yu, Y.; Schmitt, A.; Rojewski, M. T.; Chen, B.; Greiner, J.; Gotz, M.; Guillaume, P.; Dohner, H.; Bunjes, D.; Schmitt, M. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp. Hematol. 2008, 36(10), 1297-1308.
61. Weichsel, R.; Dix, C.; Wooldridge, L.; Clement, M.; Fenton-May, A.; Sewell, A. K.; Zezula, J.; Greiner, E.; Gostick, E.; Price, D. A.; Einsele, H.; Seggewiss, R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 2008, 14(8), 2484-2491.
62. Blake, S. J.; Bruce Lyons, A.; Fraser, C. K.; Hayball, J. D.; Hughes, T. P. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008, 111(8), 4415-4416.
63. Kreutzman, A.; Juvonen, V.; Kairisto, V.; Ekblom, M.; Stenke, L.; Seggewiss, R.; Porkka, K.; Mustjoki, S. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010, 116(5), 673-674.
64. Mustjoki, S.; Ekblom, M.; Arstila, T. P.; Dybedal, I.; Epling-Burnette, P. K.; Guilhot, F.; Hjorth-Hansen, H.; Hoglund, M.; Kovanen, P.; Laurinolli, T.; Liesveld, J.; Paquette, R.; Pinilla-Ibarz, J.; Rauhala, A.; Shah, N.; Simonsson, B.; Sinisalo, M.; Steegmann, J. L.; Stenke, L.; Porkka, K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23(8), 1398-1405.
65. Drobyski, W. R.; Keever, C. A.; Roth, M. S.; Koethe, S.; Hanson, G.; McFadden, P.; Gottschall, J. L.; Ash, R. C.; van Tuinen, P.; Horowitz, M. M.; Flomenberg, N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993, 82(8), 2310-2318.
66. Kolb, H. J.; Schattenberg, A.; Goldman, J. M.; Hertenstein, B.; Jacobsen, N.; Arcese, W.; Ljungman, P.; Ferrant, A.; Verdonck, L.; Niederwieser, D.; van Rhee, F.; Mittermueller, J.; de Witte, T.; Holler, E.; Ansari, H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86(5), 2041-2050.
67. Apperley, J. F.; Mauro, F. R.; Goldman, J. M.; Gregory, W.; Arthur, C. K.; Hows, J.; Arcese, W.; Papa, G.; Mandelli, F.; Wardle, D.; Gravett, P; Franklin, I. M.; Bandini, G.; Ricci, P.; Tura, S.; Iacone, A.; Torlontano, G.; Heit, W.; Champlin, R.; Gale, R. P. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. 1988, 69(2), 239-245.
68. Bleakley, M.; Riddell, S. R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 2004, 4(5), 371-380.
69. Falkenburg, J. H.; van de Corput, L.; Marijt, E. W.; Willemze, R. Minor histocompatibility antigens in human stem cell transplantation. Exp. Hematol. 2003, 31(9), 743-751.
70. Goulmy, E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997, 157, 125-140.
71. Kroger, N.; Badbaran, A.; Holler, E.; Hahn, J.; Kobbe, G.; Bornhauser, M.; Reiter, A.; Zabelina, T.; Zander, A. R.; Fehse, B. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109(3), 1316-1321.
72. Sadovnikova, E.; Stauss, H. J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 1996, 93(23), 13114-13118.
73. Horowitz, M. M.; Gale, R. P.; Sondel, P. M.; Goldman, J. M.; Kersey, J.; Kolb, H. J.; Rimm, A. A.; Ringden, O.; Rozman, C.; Speck, B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3), 555-562.
74. Cervantes, F.; Rovira, M.; Urbano-Ispizua, A.; Rozman, M.; Carreras, E.; Montserrat, E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000, 26(6), 697-699.
75. Deeg, H. J.; Gooley, T. A.; Flowers, M. E.; Sale, G. E.; Slattery, J. T.; Anasetti, C.; Chauncey, T. R.; Doney, K.; Georges, G. E.; Kiem, H. P.; Martin, P. J.; Petersdorf, E. W.; Radich, J.; Sanders, J. E.; Sandmaier, B. M.; Warren, E. H.; Witherspoon, R. P.; Storb, R.; Appelbaum, F. R. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102(12), 3912-3918.
76. Chalandon, Y.; Passweg, J. R.; Schmid, C.; Olavarria, E.; Dazzi, F.; Simula, M. P.; Ljungman, P.; Schattenberg, A.; Witte, T. D.; Lenhoff, S.; Jacobs, P.; Volin, L.; Iacobelli, S.; Finke, J.; Niederwieser, D.; Guglielmi, C. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leuke-mia working party of the EBMT. Bone Marrow Transplant 2010, 45(3), 558-564.
77. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 1999, 340(17), 1330-40.
78. Quintarelli, C.; Dotti, G.; De Angelis, B.; Hoyos, V.; Mims, M.; Luciano, L.; Heslop, H. E.; Rooney, C. M.; Pane, F.; Savoldo, B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008, 112(5), 1876-1885.
79. Molldrem, J. J.; Lee, P. P.; Kant, S.; Wieder, E.; Jiang, W.; Lu, S.; Wang, C.; Davis, M. M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 2003, 111(5), 639-647.
80. Ben-Neriah, Y.; Daley, G. Q.; Mes-Masson, A. M.; Witte, O. N.; Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986, 233(4760), 212-214.
81. de Klein, A.; van Kessel, A. G.; Grosveld, G.; Bartram, C. R.; Hagemeijer, A.; Bootsma, D.; Spurr, N. K.; Heisterkamp, N.; Groffen, J.; Stephenson, J. R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300(5894), 765-767.
82. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247(4946), 1079-1082.
83. Cathcart, K.; Pinilla-Ibarz, J.; Korontsvit, T.; Schwartz, J.; Zakhaleva, V.; Papadopoulos, E. B.; Scheinberg, D. A. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103(3), 1037-1042.
84. Holyoake, T. L.; Jiang, X.; Jorgensen, H. G.; Graham, S.; Alcorn, M. J.; Laird, C.; Eaves, A. C.; Eaves, C. J. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001, 97(3), 720-728.
85. Pinilla-Ibarz, J.; Cathcart, K.; Korontsvit, T.; Soignet, S.; Bocchia, M.; Caggiano, J.; Lai, L.; Jimenez, J.; Kolitz, J.; Scheinberg, D. A., Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95(5), 1781-1787.
86. Bocchia, M.; Korontsvit, T.; Xu, Q.; Mackinnon, S.; Yang, S. Y.; Sette, A.; Scheinberg, D. A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87(9), 3587-3592.
87. ten Bosch, G. J.; Kessler, J. H.; Joosten, A. M.; Bres-Vloemans, A. A.; Geluk, A.; Godthelp, B. C.; van Bergen, J.; Melief, C. J.; Leeksma, O. C. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999, 94(3), 1038-1045.
88. Yotnda, P.; Firat, H.; Garcia-Pons, F.; Garcia, Z.; Gourru, G.; Vernant, J. P.; Lemonnier, F. A.; Leblond, V.; Langlade-Demoyen, P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. In-vest. 1998, 101(10), 2290-2296.
89. Posthuma, E. F.; Falkenburg, J. H.; Apperley, J. F.; Gratwohl, A.; Hertenstein, B.; Schipper, R. F.; Oudshoorn, M.; Biezen, J. H.; Hermans, J.; Willemze, R.; Roosnek, E.; Niederwieser, D. HLA- DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia 2000, 14(5), 859-862.
90. Posthuma, E. F.; Falkenburg, J. H.; Apperley, J. F.; Gratwohl, A.; Roosnek, E.; Hertenstein, B.; Schipper, R. F.; Schreuder, G. M.; D'Amaro, J.; Oudshoorn, M.; van Biezen, J. H.; Hermans, J.; Willemze, R.; Niederwieser, D. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999, 93(11), 3863-3865.
91. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355(23), 2408-2417.
92. Hochhaus, A.; O'Brien, S. G.; Guilhot, F.; Druker, B. J.; Branford, S.; Foroni, L.; Goldman, J. M.; Muller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23(6), 1054-1061.
93. Rojas, J. M.; Knight, K.; Wang, L.; Clark, R. E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21(11), 2287-2295.
94. Pinilla-Ibarz, J.; Korontsvit, T.; Zakhaleva, V.; Roberts, W.; Scheinberg, D. A. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell re-sponses. Haematologica 2005, 90(10), 1324-1332.
95. Maslak, P. G.; Dao, T.; Gomez, M.; Chanel, S.; Packin, J.; Korontsvit, T.; Zakhaleva, V.; Pinilla-Ibarz, J.; Berman, E.; Scheinberg, D. A. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008, 22(8), 1613-1616.
96. Jain, N.; Reuben, J. M.; Kantarjian, H.; Li, C.; Gao, H.; Lee, B. N.; Cohen, E. N.; Ebarb, T.; Scheinberg, D. A.; Cortes, J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009, 115(17), 3924-3934.
97. [97] Grunebach, F.; Mirakaj, V.; Mirakaj, V.; Muller, M. R.; Brummendorf, T.; Brossart, P. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res. 2006, 66(11), 5892-5900.
98. Goldschmeding, R.; van der Schoot, C. E.; ten Bokkel Huinink, D.; Hack, C. E.; van den Ende, M. E.; Kallenberg, C. G.; von dem Borne, A. E. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J. Clin. Invest. 1989, 84(5), 1577-1587.
99. Dengler, R.; Munstermann, U.; al-Batran, S.; Hausner, I.; Faderl, S.; Nerl, C.; Emmerich, B. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol. 1995, 89(2), 250-257.
100. Fujiwara, H.; El Ouriaghli, F.; Grube, M.; Price, D. A.; Rezvani, K.; Gostick, E.; Sconocchia, G.; Melenhorst, J.; Hensel, N.; Douek, D. C.; Barrett, A. J. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 2004, 103(8), 3076-3083.
101. Molldrem, J. J.; Clave, E.; Jiang, Y. Z.; Mavroudis, D.; Raptis, A.; Hensel, N.; Agarwala, V.; Barrett, A. J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997, 90(7), 2529-2534.
102. Rezvani, K.; Grube, M.; Brenchley, J. M.; Sconocchia, G.; Fujiwara, H.; Price, D. A.; Gostick, E.; Yamada, K.; Melenhorst, J.; Childs, R.; Hensel, N.; Douek, D. C.; Barrett, A. J. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003, 102(8), 2892-2900.
103. Maurer, U.; Brieger, J.; Weidmann, E.; Mitrou, P. S.; Hoelzer, D.; Bergmann, L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp. Hematol. 1997, 25(9), 945-950.
104. Pritchard-Jones, K.; Fleming, S.; Davidson, D.; Bickmore, W.; Porteous, D.; Gosden, C.; Bard, J.; Buckler, A.; Pelletier, J.; Housman, D.; Heyningen, V.; Hastie, N. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990, 346(6280), 194-197.
105. Inoue, K.; Ogawa, H.; Sonoda, Y.; Kimura, T.; Sakabe, H.; Oka, Y.; Miyake, S.; Tamaki, H.; Oji, Y.; Yamagami, T.; Tatekawa, T.; Soma, T.; Kishimoto, T.; Sugiyama, H. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89(4), 1405-1412.
106. Inoue, K.; Tamaki, H.; Ogawa, H.; Oka, Y.; Soma, T.; Tatekawa, T.; Oji, Y.; Tsuboi, A.; Kim, E. H.; Kawakami, M.; Akiyama, T.; Kishimoto, T.; Sugiyama, H. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998, 91(8), 2969-2976.
107. Candoni, A.; Tiribelli, M.; Toffoletti, E.; Cilloni, D.; Chiarvesio, A.; Michelutti, A.; Simeone, E.; Pipan, C.; Saglio, G.; Fanin, R. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur. J. Haematol. 2009, 82(1), 61-68.
108. Cilloni, D.; Renneville, A.; Hermitte, F.; Hills, R. K.; Daly, S.; Jovanovic, J. V.; Gottardi, E.; Fava, M.; Schnittger, S.; Weiss, T.; Izzo, B.; Nomdedeu, J.; van der Heijden, A.; van der Reijden, B. A.; Jansen, J. H.; van der Velden, V. H.; Ommen, H.; Preudhomme, C.; Saglio, G.; Grimwade, D. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a european leukemianet study. J. Clin. Oncol. 2009, 27(31), 5195-5201.
109. Ogawa, H.; Tamaki, H.; Ikegame, K.; Soma, T.; Kawakami, M.; Tsuboi, A.; Kim, E. H.; Hosen, N.; Murakami, M.; Fujioka, T.; Masuda, T.; Taniguchi, Y.; Nishida, S.; Oji, Y.; Oka, Y.; Sugiyama, H. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101(5), 1698-1704.
110. Bellantuono, I.; Gao, L.; Parry, S.; Marley, S.; Dazzi, F.; Apperley, J.; Goldman, J. M.; Stauss, H. J. Two distinct HLA-A0201- presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002, 100(10), 3835-3837.
111. Gao, L.; Bellantuono, I.; Elsasser, A.; Marley, S. B.; Gordon, M. Y.; Goldman, J. M.; Stauss, H. J. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95(7), 2198-2203.
112. Gao, L.; Xue, S. A.; Hasserjian, R.; Cotter, F.; Kaeda, J.; Goldman, J. M.; Dazzi, F.; Stauss, H. J. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemiainitiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 2003, 75(9), 1429-1436.
113. Oka, Y.; Elisseeva, O. A.; Tsuboi, A.; Ogawa, H.; Tamaki, H.; Li, H.; Oji, Y.; Kim, E. H.; Soma, T.; Asada, M.; Ueda, K.; Maruya, E.; Saji, H.; Kishimoto, T.; Udaka, K.; Sugiyama, H. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000, 51(2), 99-107.
114. Elisseeva, O. A.; Oka, Y.; Tsuboi, A.; Ogata, K.; Wu, F.; Kim, E. H.; Soma, T.; Tamaki, H.; Kawakami, M.; Oji, Y.; Hosen, N.; Kubota, T.; Nakagawa, M.; Yamagami, T.; Hiraoka, A.; Tsukaguchi, M.; Udaka, K.; Ogawa, H.; Kishimoto, T.; Nomura, T.; Sugiyama, H. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99(9), 3272-3279.
115. Pinilla-Ibarz, J.; May, R. J.; Korontsvit, T.; Gomez, M.; Kappel, B.; Zakhaleva, V.; Zhang, R. H.; Scheinberg, D. A. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006, 20(11), 2025-2033.
116. Keilholz, U.; Letsch, A.; Busse, A.; Asemissen, A. M.; Bauer, S.; Blau, I. W.; Hofmann, W. K.; Uharek, L.; Thiel, E.; Scheibenbogen, C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(26), 6541-6548.
117. Oka, Y.; Tsuboi, A.; Taguchi, T.; Osaki, T.; Kyo, T.; Nakajima, H.; Elisseeva, O. A.; Oji, Y.; Kawakami, M.; /xnamexIkegam/x/namexe, K.; Hosen, N.; Yoshihara, S.; Wu, F.; Fujiki, F.; Murakami, M.; Masuda, T.; Nishida, S.; Shirakata, T.; Nakatsuka, S.; Sasaki, A.; Udaka, K.; Dohy, H.; Aozasa, K.; Noguchi, S.; Kawase, I.; Sugiyama, H., In-duction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA 2004, 101(38), 13885-13890.
118. Rezvani, K.; Yong, A. S.; Mielke, S.; Savani, B. N.; Musse, L.; Superata, J.; Jafarpour, B.; Boss, C.; Barrett, A. J. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111(1), 236-242.
119. Greiner, J.; Schmitt, A.; Giannopoulos, K.; Rojewski, M. T.; Goetz, M.; Funk, I.; Ringhoffer, M.; Bunjes, D.; Hofmann, S.; Ritter, G.; Döhner, H.; Schmitt, M. High dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodys-plastic syndrome (MDS) and multiple myeloma (MM). Haema-tologica 2010, 95, 1191-1197.
120. Greiner, J.; Ringhoffer, M.; Taniguchi, M.; Schmitt, A.; Kirchner, D.; Krahn, G.; Heilmann, V.; Gschwend, J.; Bergmann, L.; Dohner, H.; Schmitt, M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 2002, 30(9), 1029-1035.
121. Gething, M. J.; Sambrook, J. Protein folding in the cell. Nature 1992, 355(6355), 33-45.
122. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 2002, 20, 395-425.
123. Marin, D.; Kaeda, J. S.; Andreasson, C.; Saunders, S. M.; Bua, M.; Olavarria, E.; Goldman, J. M.; Apperley, J. F. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005, 103(9), 1850-1855.
124. Litzow, M. R.; Dietz, A. B.; Bulur, P. A.; Butler, G. W.; Gastineau, D. A.; Hoering, A.; Fink, S. R.; Letendre, L.; Padley, D. J.; Paternoster, S. F.; Tefferi, A.; Vuk-Pavlovic, S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006, 8(3), 290-298.
125. Ossenkoppele, G. J.; Stam, A. G.; Westers, T. M.; de Gruijl, T. D.; Janssen, J. J.; van de Loosdrecht, A. A.; Scheper, R. J. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003, 17(7), 1424-1426.
126. Westermann, J.; Kopp, J.; van Lessen, A.; Hecker, A. C.; Baskaynak, G.; le Coutre, P.; Dohner, K.; Dohner, H.; Dorken, B.; Pezzutto, A. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 2007, 137(4), 297-306.
127. Takahashi, T.; Tanaka, Y.; Nieda, M.; Azuma, T.; Chiba, S.; Juji, T.; Shibata, Y.; Hirai, H. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk. Res. 2003, 27(9), 795-802.
128. Vermorken, J. B.; Van Tendeloo, V. F. Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev. Anticancer Ther. 2003, 3(1), 1-3.
129. Payvandi, F.; Wu, L.; Haley, M.; Schafer, P. H.; Zhang, L. H.; Chen, R. S.; Muller, G. W.; Stirling, D. I. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL- 1beta, and LPS-stimulated human PBMC in a partially IL-10- dependent manner. Cell Immunol. 2004, 230(2), 81-88.
130. Chang, D. H.; Liu, N.; Klimek, V.; Hassoun, H.; Mazumder, A.; Nimer, S. D.; Jagannath, S.; Dhodapkar, M. V. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108(2), 618-621.
131. Tai, Y. T.; Li, X. F.; Catley, L.; Coffey, R.; Breitkreutz, I.; Bae, J.; Song, W.; Podar, K.; Hideshima, T.; Chauhan, D.; Schlossman, R.; Richardson, P.; Treon, S. P.; Grewal, I. S.; Munshi, N. C.; Anderson, K. C. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005, 65(24), 11712-11720.
132. Galustian, C.; Meyer, B.; Labarthe, M. C.; Dredge, K.; Klaschka, D.; Henry, J.; Todryk, S.; Chen, R.; Muller, G.; Stirling, D.; Schafer, P.; Bartlett, J. B.; Dalgleish, A. G. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 2009, 58(7), 1033-1045.
133. Ramsay, A. G.; Clear, A. J.; Kelly, G.; Fatah, R.; Matthews, J.; Macdougall, F.; Lister, T. A.; Lee, A. M.; Calaminici, M.; Gribben, J. G. Follicular lymphoma cells induce T-cell immunological synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114(21), 4713-4720.
134. Ramsay, A. G.; Johnson, A. J.; Lee, A. M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J. C.; Gribben, J. G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008, 118(7), 2427-2437.
135. Quintas-Cardama, A.; Kantarjian, H. M.; Manshouri, T.; Thomas, D.; Cortes, J.; Ravandi, F.; Garcia-Manero, G.; Ferrajoli, A.; Bueso-Ramos, C.; Verstovsek, S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J. Clin. Oncol. 2009, 27(28), 4760-4766.
136. Tefferi, A.; Verstovsek, S.; Barosi, G.; Passamonti, F.; Roboz, G. J.; Gisslinger, H.; Paquette, R. L.; Cervantes, F.; Rivera, C. E.; Deeg, H. J.; Thiele, J.; Kvasnicka, H. M.; Vardiman, J. W.; Zhang, Y.; Bekele, B. N.; Mesa, R. A.; Gale, R. P.; Kantarjian, H. M. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J. Clin. Oncol. 2009, 27(27), 4563-4569.
137. Li, L.; Reinhardt, P.; Schmitt, A.; Barth, T. F.; Greiner, J.; Ringhoffer, M.; Dohner, H.; Wiesneth, M.; Schmitt, M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother. 2005, 54(7), 685-693.
138. Schmitt, M.; Schmitt, A.; Rojewski, M. T.; Chen, J.; Giannopoulos, K.; Fei, F.; Yu, Y.; Gotz, M.; Heyduk, M.; Ritter, G.; Speiser, D. E.; Gnjatic, S.; Guillaume, P.; Ringhoffer, M.; Schlenk, R. F.; Liebisch, P.; Bunjes, D.; Shiku, H.; Dohner, H.; Greiner, J. RHAMM- R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111(3), 1357-1365.
139. Kawakami, M.; Oka, Y.; Tsuboi, A.; Harada, Y.; Elisseeva, O. A.; Furukawa, Y.; Tsukaguchi, M.; Shirakata, T.; Nishida, S.; Nakajima, H.; Morita, S.; Sakamoto, J.; Kawase, I.; Oji, Y.; Sugiyama, H. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int. J. Hematol. 2007, 85(5), 426-429.